BELEAN.NET: We are part-time CFO for start-ups and scale-ups in biotech and digital. We support companies in strategy, fundraising, M&A, Due Diligence, business modelling, financial controlling, implementation of internal processes and ERP. MISSION: Supported by the partners and seniors of beLean.net, you participate directly in the various CFO missions. YOU: You are passionated about start-ups and technology and you[…]
OncoDNA, the genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, will customize its interpretation platform OncoKDM to make it compatible with SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform. The combined offering will enable the analysis and automatic translation of complex genomic data obtained via SOPHiA DDM™ into actionable recommendations, empowering[…]
The current health crisis has highlighted the resilience that Belgian companies have shown to accelerate research and allow the development, in record time, of multiple therapeutic solutions to counter the Covid-19 pandemic. This social responsibility is the proof of the value that an innovative biopharmaceutical industry could bring with its expertise in dealing with an epidemic.[…]
A first-round funding of 3 millions euros has been raised by Vésale Bioscience, the spin-out of the Vésale Pharma group which focuses on phagotherapy. In order to increase its financial resources and reach the stock market, the group has hired beLean.net Partner Guillaume de Viron as Head of Finance for the phage therapy division. Co-founder of Univercells, former CFO of MaSTHerCell,[…]
Vésale Bioscience has hired Guillaume de Viron, Partner at beLean.net, as Chief Financial Officer in order to accelerate its IPO. As CFO, Guillaume de Viron will contribute to Vésale Bioscience, which is currently preparing its fundraising (10+ million €) with the aim of accelerating the production and marketing of phages. Phage therapy is the use of phages,[…]
The Brain Innovation Days hosted its first-ever Pitch Competition in January 2021. Out of 90 applications, 2 European start-ups particularly impressed the jury and the public: PIPRA, which is developing a cutting-edge AI-based pre-operative test to prevent post-operative delirium (Jury Award for Best Pitch); and icompanion, the digital companion for people with neurological conditions and their physicians (Public Award for Best Pitch).[…]
Thank you for attending the 3rd Brain Innovation Days Digital Session, Fast-tracking brain innovation in times of COVID-19 last Tuesday! We hope you enjoyed the event as much as we did and found the discussion and insight from our speakers relevant and interesting, looking at COVID-19 from a different angle and discovering potential lessons-learned to be[…]
Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]
Belgium and its companies at the forefront of the biotechnology industry in Europe Belgium is spearheading the European biotech industry. Meet some of the most successful cases of Belgian biotechnology companies. Belgium is one of the countries that provide the most to the biotech industry in Europe, as it has a total of more than[…]
Catalent Pharma takes over Delphi Genetics. The Gosselies BioPark will be its European Center of Excellence in Gene and Cell Therapy. Delphi Genetics is one of ULB‘s oldest spin-offs, created twenty years ago. The company, which employs around 40 people, is a pharmaceutical subcontracting company (CDMO) specializing in cell and gene therapies. Its mission is not to develop treatments,[…]
The Walloon Region Government to support the development of treatments at Novadip with 9.4M€ of non-dilutive funding Novadip Biosciences, a clinical-stage company developing treatments to regenerate damaged tissues in patients with significant unmet medical needs, has announced that the US Food and Drug Administration (FDA) has granted the designation of Rare Pediatric Disease and Orphan[…]
OUAT! recently raised 500k€ with the Innovation Fund. The capital infusion will support the further development of HakoBio and the roll out of the software to new clients. OUAT! aims to facilitate the digital transformation of the life sciences industry. In increasingly intelligent and connected factories, OUAT! enables the men and women of the biopharmaceutical industry to achieve[…]
Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. Univercells recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed,[…]
Many large investors have already set their sights on the Walloon company Univercells. Among them stands out the American billionaire George Soros; famous financier and philanthropist at the age of 90, Adjuvant Capital; a fund linked to the Bill Gates galaxy, the federal government through SFPI, and the Walloon government through SRIW. Bill Gates, as[…]
PDC*line Pharma attended BIO-Europe® Digital this fall 2020. Check out the interview of its CEO Eric Halioua by a journalist in an on-demand “Fireside Chat”: he presents the company strategy and how the regional ecosystem has supported the company’s development on an international scale. Contact us to get more information:
This is a world first in the field of orthopaedic surgery: surgeons at Cliniques universitaires de Saint-Luc repaired the tibia bone of a 5-year-old child using a bone graft implant, a technology developed by the UCLouvain spin-off Novadip Biosciences. The child had congenital nonunion of the tibia, a rare and disabling disease. He was[…]
Univercells has just completed a new funding round of around 50 million €. Among its investors, a fund linked to the Bill & Melinda Gates Foundation, which has already helped the Walloon biotech on several occasions. The list of investors includes Adjuvant Global Health Technology Fund, a fund originally linked to the Bill & Melinda Gates Foundation, which[…]
Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Novadip Biosciences, a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it will unveil details of its 3M3 miRNA delivery platform in a recorded presentation at the BIO Digital conference, which is took place[…]
Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]
Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html